Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

This article was originally published in PharmAsia News

Executive Summary

Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.

You may also be interested in...

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.

Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 1 of 2)

Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.

Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin

Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts